Abstract

Aim. To identify the optimal tactics of antihypertensive therapy (AHT) in patients with hypertensive crise (HC), complicated by haemorrhagic stroke (HS).Material and methods. Forty patients aged 46–87 years, who were hospitalised with HC and HS as its complication.Results. All patients were divided into two groups, according to the median levels of systolic blood pressure (SBP) at 20 minutes after the start of the treatment: SBP >161 mm Hg vs. SBP <161 mm Hg. A significantly better survival was observed in patients with a higher degree of the 20-minute SBP eduction. In addition, patients were divided into tertiles of the 20-minute SBP levels. Participants with SBP 136–149 mm Hg demonstrated a significantly better survival. The degree of SBP reduction at 220 minutes was not significantly associated with survival. Furthermore, the patients were divided into two groups by the rate of SBP reduction. Faster rates were associated with a better survival (PGW=0,002). The second part of the study was focused on the assessment of effectiveness and safety of urapidil hydrochloride (Ebrantil). The patients were randomised into two groups: one group was administered Ebrantil, while another received the standard neuroresuscitation unit treatment. Ebrantil therapy demonstrated a fast and effective SBP reduction at 20 minutes, which was also associated with a better survival.Conclusion. We identified optimal, associated with a better survival, BP levels (136–149 mm Hg) for patients with HC complicated by HS. Target BP levels should be achieved within 20 minutes, as a slower BP reduction is linked to a worse prognosis. Ebrantil is an effective and safe antihypertensive medication.

Highlights

  • We identified optimal, associated with a better survival, BP levels (136–149 mm Hg) for patients with hypertensive crise (HC) complicated by haemorrhagic stroke (HS)

  • Предварительные результаты исследования ATACH II согласуются с данными INTERACT — интенсивное снижение систолического артериального давления (САД) в остром периоде геморрагическим мозговым инсультом (ГМИ) уменьшает размер гематомы [11]

  • Эбрантил — безопасный и эффективный антигипертензивных препаратов (АГП), обеспечивающий быстрое и эффективное снижение артериальное давление (АД) к 20 мин от начала лечения, что обуславливало лучшую выживаемость

Read more

Summary

Introduction

Ebrantil therapy demonstrated a fast and effective SBP reduction at 20 minutes, which was associated with a better survival. Поскольку в этом исследовании не было оценено влияние на смертность и функциональный исход пациентов, в настоящее время проводится крупное, рандомизированное, клиническое исследование INTERACT II для определения влияния лечения на исходы заболевания у различных категорий больных ГМИ. Предварительные результаты исследования ATACH II согласуются с данными INTERACT — интенсивное снижение САД в остром периоде ГМИ уменьшает размер гематомы [11]. 1 Кумулятивная выживаемость пациентов, разделенных по медиане САД к 20 мин лечения (кривые КапланаМейера), n=40.

Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.